Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,933 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lipid Disorder Clear all
Completed Phase 1 Interventional

Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome

NCT01845428
View directory record Official record
Conditions
Nephrotic Syndrome, Hyperlipidemia
Interventions
Pravastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease

NCT02489344
View directory record Official record
Conditions
Fabry Disease
Interventions
GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

NCT00082628
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Placebo, Serostim® 4 mg, Serostim® 2 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 29, 2026, 2:35 AM EDT
Completed No phase listed Observational

Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis

NCT00921011
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
40 Years and older · Female only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Technology-Assisted Cholesterol Trial in Consumers (TACTiC)

NCT04964544
View directory record Official record
Conditions
High Cholesterol
Interventions
5 mg rosuvastatin calcium with a Web App (combination product)
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

NCT01507831
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
115
States / cities
Huntsville, Alabama • Gilbert, Arizona • Sierra Vista, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Results available

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

NCT00477594
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 29, 2026, 2:35 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

NCT07219602
View directory record Official record
Conditions
Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
32
States / cities
Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Meal Composition on Blood Lipids

NCT02529709
View directory record Official record
Conditions
Dyslipidemia
Interventions
High-Protein Condition, High-Monounsaturated Fat Condition
Other
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 29, 2026, 2:35 AM EDT
Completed No phase listed Observational

Gene Therapy for Tay-Sachs Disease

NCT01869270
View directory record Official record
Conditions
Tay Sachs Disease, Sandhoff Disease, Late Onset Tay Sachs Disease
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Tampa, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 29, 2026, 2:35 AM EDT
Terminated No phase listed Interventional Results available

Vestibular Stimulation to Trigger Adipose Loss Clinical Trial

NCT03138369
View directory record Official record
Conditions
Obesity, Obesity, Abdominal, Metabolic Syndrome, Weight Loss
Interventions
Vestibular nerve stimulator, Sham vestibular stimulation
Device
Lead sponsor
Neurovalens Ltd.
Industry
Eligibility
22 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 29, 2026, 2:35 AM EDT
Not listed Not applicable Interventional

Identification of Undiagnosed Gaucher Disease

NCT01716741
View directory record Official record
Conditions
Gaucher Disease
Interventions
Enzyme analysis
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 29, 2026, 2:35 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

NCT01675154
View directory record Official record
Conditions
Type 1 Hyperlipoproteinemia
Interventions
SLx-4090 placebo, Orlistat Placebo, Orlistat, Slx-4090
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity

NCT02043405
View directory record Official record
Conditions
Diabetes, Pre-diabetes
Interventions
Weight loss and exercise training intervention, Weight loss Only Intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Not applicable Interventional

Improving Adherence to Prescribing Guidelines for Cholesterol Lowering in Hospitalized Diabetic Patients

NCT01113099
View directory record Official record
Conditions
Diabetes, Dyslipidemia
Interventions
Academic detailing
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Phase 3 Interventional

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
45 Years to 85 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Not applicable Interventional

Reducing Disparities in Primary Prevention of Cardiovascular Disease

NCT01610609
View directory record Official record
Conditions
Cardiovascular Diseases, Cholesterol, LDL
Interventions
Population Health Management Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
35 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Flagstaff, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting Phase 2 Interventional

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

NCT05488431
View directory record Official record
Conditions
Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
Interventions
Bempedoic acid, Placebo
Drug · Other
Lead sponsor
Priscilla Hsue, MD
Other
Eligibility
40 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

NCT00286429
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and insulin, Insulin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Phoenix, Arizona • Anaheim, California • Artesia, California + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Results available

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

NCT04270760
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Beverly Hills, California • Boca Raton, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting No phase listed Observational

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

NCT00358943
View directory record Official record
Conditions
Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2034
U.S. locations
86
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Completed Not applicable Interventional Results available

A Mobile Personal Health Record for Behavioral Health Homes

NCT01890226
View directory record Official record
Conditions
Hypertension, Hyperlipidemia, Diabetes
Interventions
Mobile Personal Health Record App.
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Conyers, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 29, 2026, 2:35 AM EDT
Recruiting No phase listed Observational

MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)

NCT05586243
View directory record Official record
Conditions
Gaucher Disease, Type 3
Interventions
No intervention
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 29, 2026, 2:35 AM EDT
Terminated Phase 3 Interventional

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

NCT00741715
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AVE5530, atorvastatin, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 29, 2026, 2:35 AM EDT